Significance of the Preoperative Intravesical Instillation of Doxorubicin and the Oral Administration of 5-Fluorouracil in Preventing Recurrence after a Transurethral Resection of Superficial Bladder Cancer

International Journal of Urology

Volumn 4, Issue 4, 1997, Pages 352-357

  Naito, Seiji ^a   Iguchi, Atsushi ^b   Sagiyama, Kazuyuki ^c   Ariyoshi, Asami ^d   Osada, Yukio ^e   Omoto, Tetsuo ^f   Kuriya, Norikazu ^g   Kumazawa, Joichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c HARASANSHIN HOSPITAL   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

^e UNIVERSITY OF MIYAZAKI   (Japan)

^f KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Doxorubicin; Intravesical instillation; Recurrence; Superficial bladder cancer

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0031183762     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1997.tb00207.x     Document Type: Article

References (14)

1. Soloway MS, Martino CC. Prophylaxis of bladder tumor implantation: intravesical and systemic chemotherapy. Urology 1976;7:29-34.
2. Soloway MS. Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 1980;123:461-466.
3. Spaulding JT. Intravesical chemotherapy in the United States. Cancer Chemother Pharmacol 1983;11 (suppl):5-8.
4. Niijima T, Koiso K, Akaza H, the Japanese Urological Cancer Research Group for Adriamycin. Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 1983;11(suppl):79-82.
5. Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Maru A, Matsumura Y, Niijima T, Obata K, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Uyama T, the Japanese Urological Cancer Research Group for Adriamycin. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol 1987;20(suppl):91-96.
6. Ueda T, Naito S, Iguchi A, Sagiyama K, Osada Y, Ariyoshi A, Omoto T, Kumazawa J, The Kyushu University Urological Oncology Group. Adjuvant chemotherapy with early intravesical instillation of Adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. Cancer Chemother Pharmacol 1992;30(suppl):31-36.
7. Matsumura Y, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Niijima T, Obata K, Ohashi Y, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, the Japanese Urological Cancer Research Group for Adriamycin. The 4th study of prophylactic intravesical chemotherapy with Adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 1992;30(suppl):10-14.
8. Obata K, Ohashi Y, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, the Japanese Urological Cancer Research Group for Adriamycin. Prophylactic chemotherapy with intravesical instillation of Adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. Cancer Chemother Pharmacol 1994; 35(suppl):88-92.
9. Bono AV. Superficial bladder cancer: state of the art. Cancer Chemother Pharmacol 1994;35(suppl):101-109.
10. Van der Meijden APM, Kurth K-H, Oosterlinck W, Debruyne FMJ, EORTC Genito-Urinary Group. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol 1992;30(suppl):95-98.
11. Weisenthal LM, Lalude AO, Millwe FB. In vitro chemosensitivity of human bladder cancer. Cancer 1983;51:1490-1496.
12. Ohmori H, Matsumura Y, Yoshimoto J, Obama T, Hara M, Josen Y, Ishido N, Nasu Y, Tanahashi T, Asai T, Ike N, Akazawa N, Tsushima T, Tanaka H, Furukawa Y. A phase II study of 5-FU tablets for bladder tumors. Jpn J Cancer Chemother 1988; 15:3115-3120.
13. Nagamoto A, Kubota Y, Shuin T, Moriyama M, Satomi Y, Fukushima S, Fukuoka H, Ishizuka E, Furuhata A, Yoshimura S, Matsuura K, Kumagai H, Ida T, Hirokawa M, Nakahashi M, Misaki H, Hosaka M. Phase II study of 5-FU tablets for bladder tumors. Jpn J Cancer Chemother 1989;16:845-849.
14. Fossa SD, Gudmundsen TE. Single drug chemotherapy with 5-FU and Adriamycin in metastatic bladder carcinoma. Br J Urol 1981;53:320-323.